DRNA - Dicerna Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $3.46. This is a potential upside of $3.46 (0%) from yesterday's end of day stock price of $0.

Dicerna Pharmaceuticals's activity chart (see below) currently has 90 price targets and 56 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 76.59% with an average time for these price targets to be met of 309.55 days.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 10-Dec-2021. First documented stock forecast 13-Mar-2015.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$38.25

$0.03 (0.08%)

3 years 2 months 21 days ago
(10-Dec-2021)

1/2 (50%)

$0.34 (0.90%)

101

Buy

$30

$-8.22 (-21.51%)

$30

3 years 3 months 13 days ago
(19-Nov-2021)

2/3 (66.67%)

$-7.92 (-20.89%)

250

Hold

$35

$-3.22 (-8.42%)

$35

3 years 3 months 13 days ago
(18-Nov-2021)

3/6 (50%)

$-3.03 (-7.97%)

168

Hold

$38

$-0.22 (-0.58%)

$42

3 years 3 months 13 days ago
(18-Nov-2021)

8/10 (80%)

$-0.03 (-0.08%)

260

Buy

$25

$-13.22 (-34.59%)

3 years 6 months 21 days ago
(10-Aug-2021)

5/8 (62.5%)

$2.81 (12.66%)

195

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DRNA (Dicerna Pharmaceuticals) average time for price targets to be met?

On average it took 309.55 days on average for the stock forecasts to be realized with a an average price target met ratio 76.59

Which analyst has the current highest performing score on DRNA (Dicerna Pharmaceuticals) with a proven track record?

MAYANK MAMTANI

Which analyst has the most public recommendations on DRNA (Dicerna Pharmaceuticals)?

Mayank Mamtani works at B. RILEY and has 8 price targets and 5 ratings on DRNA

Which analyst is the currently most bullish on DRNA (Dicerna Pharmaceuticals)?

Keay Nakae with highest potential upside - $0.03

Which analyst is the currently most reserved on DRNA (Dicerna Pharmaceuticals)?

Edward Nash with lowest potential downside - -$18.22

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?